Proposed Data Collection Submitted for Public Comment and Recommendations, 79923-79925 [2024-22475]
Download as PDF
<![CDATA[
79923
Federal Register / Vol. 89, No. 190 / Tuesday, October 1, 2024 / Notices
services, and aged 21–64 years for
cervical cancer services; and under- or
uninsured.
CDC proposes revisions to three of the
previously approved information
collection instruments:
Annual NBCCEDP Survey—This
instrument collects program-level
information annually to monitor
recipients’ challenges, external funding
sources, partnerships, and EBI
implementation. The survey has been
revised to include new survey questions
to improve data quality for items related
to partnership activities and recipients’
requirements for patients’ payments
towards screening services, as well as
the removal of a COVID–19 related
question.
Clinic-Level Data Collection Tool—
This instrument collects clinic-level
data at baseline and annually to assess
health system, clinic, and patient
population characteristics; monitoring
and quality improvement activities; EBI
implementation; and baseline or annual
current best practices for demographic
questions related to sexual orientation
and gender identity (SOGI) and race and
ethnicity (R/E) at this time. However,
CDC plans to revise information
collections that include demographic
items to align with HHS’ SOGI and R/
E guidelines for the next funding cycle
beginning in 2027.
The proposed information collections
will allow CDC to better gauge progress
in meeting NBCCEDP program goals and
monitor implementation activities,
evaluate outcomes, and identify
awardee technical assistance needs. In
addition, findings will inform program
improvement and help identify
successful activities that need to be
maintained, replicated, or expanded.
OMB approval is requested for three
years. CDC requests OMB approval for
an estimated 1,162 annual burden
hours. Participation is required for
NBCCEDP awardees. There are no costs
to respondents other than their time.
screening rates. This tool has been
revised to remove COVID–19 related
variables and update response options
for the measures used to report breast
and cervical cancer screening rates.
QPU—This instrument collects
program-level data four times per year
to monitor award spending, service
delivery, staff vacancies, program
challenges and successes, and TA
needs. This instrument has been revised
to include two optional open-ended
items to allow recipients to provide
context to reported service delivery and
spending data only if needed.
CDC proposes continued use of the
remaining two information collections;
Service Delivery Project Worksheet and
the MDEs, which have not been
changed. To maximize consistency in
our routine data collections for the
current NBCCEDP funding cycle, CDC
has not revised NBCCEDP information
collections to align with the Department
of Health and Human Services (HHS)’
ESTIMATED ANNUALIZED BURDEN HOURS
Form name
NBCCEDP Awardees .......................
Annual NBCCEDP Survey ...............
NBCCEDP Clinic-level Information
Collection Instrument—Breast.
NBCCEDP Clinic-level Information
Collection Instrument—Cervical.
Quarterly Program Update ...............
Service Delivery Projection Worksheet.
MDEs ................................................
Total ...........................................
...........................................................
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Public Health Ethics and
Regulations, Office of Science, Centers for
Disease Control and Prevention.
[FR Doc. 2024–22477 Filed 9–30–24; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
khammond on DSKJM1Z7X2PROD with NOTICES
Number of
respondents
Type of respondents
[60Day—24–24IW; Docket No. CDC–2024–
0070]
Proposed Data Collection Submitted
for Public Comment and
Recommendations
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
AGENCY:
VerDate Sep<11>2014
17:42 Sep 30, 2024
Jkt 265001
ACTION:
1
6
46/60
40/60
54
284
71
6
40/60
284
71
71
4
1
22/60
29/60
151
34
71
2
150/60
355
........................
........................
........................
1,162
Notice with comment period.
The Centers for Disease
Control and Prevention (CDC), as part of
its continuing effort to reduce public
burden and maximize the utility of
government information, invites the
general public and other federal
agencies the opportunity to comment on
a proposed information collection, as
required by the Paperwork Reduction
Act of 1995. This notice invites
comment on a proposed information
collection project titled Becton
Dickinson BACTECTM Blood Culture
Media Bottles Shortage Impact
Questionnaire, which will assess the
impact of the Becton Dickinson (BD)
BACTECTM blood culture media bottles
supply shortage on individual facilities
and how CDC NHSN bloodstream
infection surveillance might be affected.
Frm 00039
Fmt 4703
Total burden
(in hours)
71
71
SUMMARY:
PO 00000
Average
burden per
response
(in hours)
Number of
responses per
respondent
Sfmt 4703
CDC must receive written
comments on or before December 2,
2024.
DATES:
You may submit comments,
identified by Docket No. CDC–2024–
0070 by either of the following methods:
• Federal eRulemaking Portal:
www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: Jeffrey M. Zirger, Information
Collection Review Office, Centers for
Disease Control and Prevention, 1600
Clifton Road NE, MS H21–8, Atlanta,
Georgia 30329.
Instructions: All submissions received
must include the agency name and
Docket Number. CDC will post, without
change, all relevant comments to
www.regulations.gov.
Please note: Submit all comments
through the Federal eRulemaking portal
(www.regulations.gov) or by U.S. mail to
the address listed above.
ADDRESSES:
E:\FR\FM\01OCN1.SGM
01OCN1
79924
Federal Register / Vol. 89, No. 190 / Tuesday, October 1, 2024 / Notices
To
request more information on the
proposed project or to obtain a copy of
the information collection plan and
instruments, contact Jeffrey M. Zirger,
Information Collection Review Office,
Centers for Disease Control and
Prevention, 1600 Clifton Road NE, MS
H21–8, Atlanta, Georgia 30329;
Telephone: 404–639–7570; Email: omb@
cdc.gov.
SUPPLEMENTARY INFORMATION: Under the
Paperwork Reduction Act of 1995 (PRA)
(44 U.S.C. 3501–3520), federal agencies
must obtain approval from the Office of
Management and Budget (OMB) for each
collection of information they conduct
or sponsor. In addition, the PRA also
requires federal agencies to provide a
60-day notice in the Federal Register
concerning each proposed collection of
information, including each new
proposed collection, each proposed
extension of existing collection of
information, and each reinstatement of
previously approved information
collection before submitting the
collection to the OMB for approval. To
comply with this requirement, we are
publishing this notice of a proposed
data collection as described below.
The OMB is particularly interested in
comments that will help:
1. Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
2. Evaluate the accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
3. Enhance the quality, utility, and
clarity of the information to be
collected;
4. Minimize the burden of the
collection of information on those who
are to respond, including through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submissions
of responses; and
FOR FURTHER INFORMATION CONTACT:
5. Assess information collection costs.
Proposed Project
National Healthcare Safety Network
(NHSN) Becton Dickinson BACTECTM
Blood Culture Media Bottles Shortage
Impact Questionnaire—New—National
Center for Emerging and Zoonotic
Infection Diseases (NCEZID), Centers for
Disease Control and Prevention (CDC).
Background and Brief Description
The Division of Healthcare Quality
Promotion (DHQP), National Center for
Emerging and Zoonotic Infectious
Diseases (NCEZID), Centers for Disease
Control and Prevention (CDC) collects
data from healthcare facilities in the
National Healthcare Safety Network
(NHSN) under OMB Control No. 0920–
0666. NHSN provides facilities, health
departments, states, regions, and the
nation with data necessary to identify
problem areas, measure the progress of
prevention efforts, and ultimately
eliminate healthcare-associated
infections (HAIs) nationwide. NHSN
also allows healthcare facilities to track
blood safety errors and various HAI
prevention practice methods such as
healthcare personnel influenza vaccine
status and corresponding infection
control adherence rates. Enrollment in
NHSN has continuously increased, with
over 37,000 actively reporting
healthcare facilities across the U.S. Of
the total enrolled healthcare facilities,
there are over 6,000 acute care facilities.
NHSN currently has eight components,
and the collection of information is
authorized by the Public Health Service
Act (42 U.S.C. 242b, 242k, and 242m
(d)).
Data reported under NHSN’s Patient
Safety Component are used to determine
the magnitude of the healthcareassociated adverse events and trends in
the rates of the events, in the
distribution of pathogens, and in the
adherence to prevention practices. Data
will help detect changes in the
epidemiology of adverse events
resulting from new medical therapies
and changing patient risks.
Additionally, reported data is being
used to describe the epidemiology of
antimicrobial use and resistance and to
better understand the relationship of
antimicrobial therapy to this rising
problem.
NHSN’s data is used to aid in the
tracking of HAIs and guide infection
prevention activities/practices that
protect patients. The Centers for
Medicare and Medicaid Services (CMS)
and other payers use these data to
determine incentives for performance at
healthcare facilities across the US and
surrounding territories, and members of
the public may use some protected data
to inform their selection among
available providers. Each of these
parties is dependent on the
completeness and accuracy of the data.
CDC and CMS work closely and are
fully committed to ensuring complete
and accurate reporting, which are
critical for protecting patients and
guiding national, state, and local
prevention priorities.
The U.S. Food and Drug
Administration (FDA) posted an
announcement regarding interruptions
in the supply of Becton Dickinson (BD)
BACTEC (TM) blood culture media
bottles because of recent supplier issues.
The disruption in the supply is
expected to impact patient diagnosis,
follow-up patient management, and
antimicrobial stewardship efforts. The
FDA and other entities recommend that
facilities, laboratories, and health care
providers consider conservation
strategies to prioritize the use of blood
culture media bottles, preserving the
supply for patients at highest risk. This
information collection request includes
a new data collection instrument that
will assess the impact of the supply
shortage on individual facilities and
how CDC NHSN bloodstream infection
surveillance might be affected. Facilities
enrolled in the NHSN Patient Safety
Component will be asked questions
regarding the impact of the Becton
Dickinson (BD) BACTEC (TM) blood
culture media bottles for their facility.
The questions will be collected
electronically via the NHSN application.
CDC requests OMB approval for an
estimated 2,334 annual burden hours.
There are no cost to respondents other
than their time to participate.
khammond on DSKJM1Z7X2PROD with NOTICES
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Type of respondents
Form name
Infection Preventionist/Microbiologist
Blood Culture Bottle Shortage
Questionnaire (Jul–Oct).
Blood Culture Bottle Shortage
Questionnaire (Nov–Mar).
Infection Preventionist/Microbiologist
VerDate Sep<11>2014
17:42 Sep 30, 2024
Jkt 265001
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
Number of
responses
per
respondent
Average
burden per
response
(in hours)
Total
burden
(in hours)
3,500
1
20/60
1,167
3,500
1
20/60
1,167
E:\FR\FM\01OCN1.SGM
01OCN1
Federal Register / Vol. 89, No. 190 / Tuesday, October 1, 2024 / Notices
79925
ESTIMATED ANNUALIZED BURDEN HOURS—Continued
Form name
Number of
respondents
Number of
responses
per
respondent
Average
burden per
response
(in hours)
...........................................................
........................
........................
........................
Type of respondents
Total ...........................................
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Public Health Ethics and
Regulations, Office of Science, Centers for
Disease Control and Prevention.
[FR Doc. 2024–22475 Filed 9–30–24; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60Day–24–24IV; Docket No. CDC–2024–
0071]
Proposed Data Collection Submitted
for Public Comment and
Recommendations
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice with comment period.
AGENCY:
The Centers for Disease
Control and Prevention (CDC), as part of
its continuing effort to reduce public
burden and maximize the utility of
government information, invites the
general public and other federal
agencies the opportunity to comment on
a proposed information collection, as
required by the Paperwork Reduction
Act of 1995. This notice invites
comment on a proposed information
collection project titled
‘‘Comprehensive Evaluation of the
Implementation and Uptake of the CDC
Clinical Practice Guideline for
Prescribing Opioids for Pain’’. This data
collection is designed to allow CDC to
evaluate the 2022 CDC Clinical Practice
Guidelines for opioid prescription
practices.
SUMMARY:
CDC must receive written
comments on or before December 2,
2024.
DATES:
You may submit comments,
identified by Docket No. CDC–2024–
0071 by either of the following methods:
• Federal eRulemaking Portal:
www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: Jeffrey M. Zirger, Information
Collection Review Office, Centers for
Disease Control and Prevention, 1600
khammond on DSKJM1Z7X2PROD with NOTICES
ADDRESSES:
VerDate Sep<11>2014
17:42 Sep 30, 2024
Jkt 265001
Clifton Road NE, MS H21–8, Atlanta,
Georgia 30329.
Instructions: All submissions received
must include the agency name and
Docket Number. CDC will post, without
change, all relevant comments to
www.regulations.gov.
Please note: Submit all comments
through the Federal eRulemaking portal
(www.regulations.gov) or by U.S. mail to
the address listed above.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the information collection plan and
instruments, contact Jeffrey M. Zirger,
Information Collection Review Office,
Centers for Disease Control and
Prevention, 1600 Clifton Road NE, H
21–8, Atlanta, Georgia 30329;
Telephone: 404–639–7570; Email: omb@
cdc.gov.
SUPPLEMENTARY INFORMATION: Under the
Paperwork Reduction Act of 1995 (PRA)
(44 U.S.C. 3501–3520), federal agencies
must obtain approval from the Office of
Management and Budget (OMB) for each
collection of information they conduct
or sponsor. In addition, the PRA also
requires federal agencies to provide a
60-day notice in the Federal Register
concerning each proposed collection of
information, including each new
proposed collection, each proposed
extension of existing collection of
information, and each reinstatement of
previously approved information
collection before submitting the
collection to the OMB for approval. To
comply with this requirement, we are
publishing this notice of a proposed
data collection as described below.
The OMB is particularly interested in
comments that will help:
1. Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
2. Evaluate the accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
3. Enhance the quality, utility, and
clarity of the information to be
collected;
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
Total
burden
(in hours)
2,334
4. Minimize the burden of the
collection of information on those who
are to respond, including through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submissions
of responses; and
5. Assess information collection costs.
Proposed Project
Comprehensive Evaluation of the
Implementation and Uptake of the CDC
Clinical Practice Guideline for
Prescribing Opioids for Pain—New—
National Center for Injury Prevention
and Control (NCIPC), Centers for
Disease Control and Prevention (CDC).
Background and Brief Description
Beginning in the 1990s, opioid
prescribing rates for pain management
steadily increased until 2010, remained
steady until 2012, and have declined
since then. The increase in opioid
prescribing rates corresponded with
increases in opioid-involved overdose
deaths, which initially primarily
involved prescription opioids (natural
and semi-synthetic opioids and
methadone). In response to this
emerging crisis, CDC issued the CDC
Guideline for Prescribing Opioids for
Chronic Pain—United States, 2016
(2016 CDC Guideline). Implementing
the 2016 CDC Guideline was associated
with reductions in opioid prescribing
and increases in use of non-opioid
medications for pain. At the same time,
laws and policies related to prescribing
opioids were instituted that misapplied
or were inconsistent with the 2016 CDC
Guideline, potentially contributing to
patient harm. In 2022, CDC released the
CDC Clinical Practice Guideline for
Prescribing Opioids for Pain—United
States, 2022, which provided up to date
evidence regarding pain management
approaches and re-emphasizes the need
for prescribers to be focused on patientcentered care to provide effective pain
management. CDC is comprehensively
evaluating the uptake, implementation,
and outcomes of the 2022 CDC Clinical
Practice Guideline on evidence-based
care for pain management to understand
its impact.
E:\FR\FM\01OCN1.SGM
01OCN1
]]>Agencies
[Federal Register Volume 89, Number 190 (Tuesday, October 1, 2024)]
[Notices]
[Pages 79923-79925]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-22475]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[60Day--24-24IW; Docket No. CDC-2024-0070]
Proposed Data Collection Submitted for Public Comment and
Recommendations
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice with comment period.
-----------------------------------------------------------------------
SUMMARY: The Centers for Disease Control and Prevention (CDC), as part
of its continuing effort to reduce public burden and maximize the
utility of government information, invites the general public and other
federal agencies the opportunity to comment on a proposed information
collection, as required by the Paperwork Reduction Act of 1995. This
notice invites comment on a proposed information collection project
titled Becton Dickinson BACTEC\TM\ Blood Culture Media Bottles Shortage
Impact Questionnaire, which will assess the impact of the Becton
Dickinson (BD) BACTEC\TM\ blood culture media bottles supply shortage
on individual facilities and how CDC NHSN bloodstream infection
surveillance might be affected.
DATES: CDC must receive written comments on or before December 2, 2024.
ADDRESSES: You may submit comments, identified by Docket No. CDC-2024-
0070 by either of the following methods:
Federal eRulemaking Portal: www.regulations.gov. Follow
the instructions for submitting comments.
Mail: Jeffrey M. Zirger, Information Collection Review
Office, Centers for Disease Control and Prevention, 1600 Clifton Road
NE, MS H21-8, Atlanta, Georgia 30329.
Instructions: All submissions received must include the agency name
and Docket Number. CDC will post, without change, all relevant comments
to www.regulations.gov.
Please note: Submit all comments through the Federal eRulemaking
portal (www.regulations.gov) or by U.S. mail to the address listed
above.
[[Page 79924]]
FOR FURTHER INFORMATION CONTACT: To request more information on the
proposed project or to obtain a copy of the information collection plan
and instruments, contact Jeffrey M. Zirger, Information Collection
Review Office, Centers for Disease Control and Prevention, 1600 Clifton
Road NE, MS H21-8, Atlanta, Georgia 30329; Telephone: 404-639-7570;
Email: [email protected].
SUPPLEMENTARY INFORMATION: Under the Paperwork Reduction Act of 1995
(PRA) (44 U.S.C. 3501-3520), federal agencies must obtain approval from
the Office of Management and Budget (OMB) for each collection of
information they conduct or sponsor. In addition, the PRA also requires
federal agencies to provide a 60-day notice in the Federal Register
concerning each proposed collection of information, including each new
proposed collection, each proposed extension of existing collection of
information, and each reinstatement of previously approved information
collection before submitting the collection to the OMB for approval. To
comply with this requirement, we are publishing this notice of a
proposed data collection as described below.
The OMB is particularly interested in comments that will help:
1. Evaluate whether the proposed collection of information is
necessary for the proper performance of the functions of the agency,
including whether the information will have practical utility;
2. Evaluate the accuracy of the agency's estimate of the burden of
the proposed collection of information, including the validity of the
methodology and assumptions used;
3. Enhance the quality, utility, and clarity of the information to
be collected;
4. Minimize the burden of the collection of information on those
who are to respond, including through the use of appropriate automated,
electronic, mechanical, or other technological collection techniques or
other forms of information technology, e.g., permitting electronic
submissions of responses; and
5. Assess information collection costs.
Proposed Project
National Healthcare Safety Network (NHSN) Becton Dickinson
BACTEC\TM\ Blood Culture Media Bottles Shortage Impact Questionnaire--
New--National Center for Emerging and Zoonotic Infection Diseases
(NCEZID), Centers for Disease Control and Prevention (CDC).
Background and Brief Description
The Division of Healthcare Quality Promotion (DHQP), National
Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Centers
for Disease Control and Prevention (CDC) collects data from healthcare
facilities in the National Healthcare Safety Network (NHSN) under OMB
Control No. 0920-0666. NHSN provides facilities, health departments,
states, regions, and the nation with data necessary to identify problem
areas, measure the progress of prevention efforts, and ultimately
eliminate healthcare-associated infections (HAIs) nationwide. NHSN also
allows healthcare facilities to track blood safety errors and various
HAI prevention practice methods such as healthcare personnel influenza
vaccine status and corresponding infection control adherence rates.
Enrollment in NHSN has continuously increased, with over 37,000
actively reporting healthcare facilities across the U.S. Of the total
enrolled healthcare facilities, there are over 6,000 acute care
facilities. NHSN currently has eight components, and the collection of
information is authorized by the Public Health Service Act (42 U.S.C.
242b, 242k, and 242m (d)).
Data reported under NHSN's Patient Safety Component are used to
determine the magnitude of the healthcare-associated adverse events and
trends in the rates of the events, in the distribution of pathogens,
and in the adherence to prevention practices. Data will help detect
changes in the epidemiology of adverse events resulting from new
medical therapies and changing patient risks. Additionally, reported
data is being used to describe the epidemiology of antimicrobial use
and resistance and to better understand the relationship of
antimicrobial therapy to this rising problem.
NHSN's data is used to aid in the tracking of HAIs and guide
infection prevention activities/practices that protect patients. The
Centers for Medicare and Medicaid Services (CMS) and other payers use
these data to determine incentives for performance at healthcare
facilities across the US and surrounding territories, and members of
the public may use some protected data to inform their selection among
available providers. Each of these parties is dependent on the
completeness and accuracy of the data. CDC and CMS work closely and are
fully committed to ensuring complete and accurate reporting, which are
critical for protecting patients and guiding national, state, and local
prevention priorities.
The U.S. Food and Drug Administration (FDA) posted an announcement
regarding interruptions in the supply of Becton Dickinson (BD) BACTEC
(TM) blood culture media bottles because of recent supplier issues. The
disruption in the supply is expected to impact patient diagnosis,
follow-up patient management, and antimicrobial stewardship efforts.
The FDA and other entities recommend that facilities, laboratories, and
health care providers consider conservation strategies to prioritize
the use of blood culture media bottles, preserving the supply for
patients at highest risk. This information collection request includes
a new data collection instrument that will assess the impact of the
supply shortage on individual facilities and how CDC NHSN bloodstream
infection surveillance might be affected. Facilities enrolled in the
NHSN Patient Safety Component will be asked questions regarding the
impact of the Becton Dickinson (BD) BACTEC (TM) blood culture media
bottles for their facility. The questions will be collected
electronically via the NHSN application.
CDC requests OMB approval for an estimated 2,334 annual burden
hours. There are no cost to respondents other than their time to
participate.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Number of Average burden
Type of respondents Form name Number of responses per per response Total burden
respondents respondent (in hours) (in hours)
----------------------------------------------------------------------------------------------------------------
Infection Preventionist/ Blood Culture 3,500 1 20/60 1,167
Microbiologist. Bottle Shortage
Questionnaire
(Jul-Oct).
Infection Preventionist/ Blood Culture 3,500 1 20/60 1,167
Microbiologist. Bottle Shortage
Questionnaire
(Nov-Mar).
---------------------------------------------------------------------------------
[[Page 79925]]
Total..................... ................ .............. .............. .............. 2,334
----------------------------------------------------------------------------------------------------------------
Jeffrey M. Zirger,
Lead, Information Collection Review Office, Office of Public Health
Ethics and Regulations, Office of Science, Centers for Disease Control
and Prevention.
[FR Doc. 2024-22475 Filed 9-30-24; 8:45 am]
BILLING CODE 4163-18-P
